Advertisement
Advertisement

CRSP

CRSP logo

CRISPR Therapeutics AG

54.43
USD
Sponsored
+0.44
+0.82%
Jun 24, 10:03 UTC -4
Open

CRISPR Therapeutics AG Profile

About

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

Info & Links

CEO

Samarth Kulkarni

Headquarters

BAARERSTRASSE 14
ZUG, V8 CH-6300, SWITZERLAND

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.crisprtx.com

Auditor

Ernst & Young LLP

Share holders

17

Employees

0

CRISPR Therapeutics AG Statistics

Valuation Measures

Market Capitalization2

5.36B

Enterprise Value

5.52B

Enterprise Value/EBITDA(ttm)

-8.80

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

1.41K

Price to Book(mrq)

2.56

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-13827.52%

Profit Margin(ttm)

-16548.09%

Return on Equity(ttm)

-26.31%

Return on Invested Capital(ttm)

-31.97%

Return on Assets(ttm)

-22.30%

Income Statement

Revenue(ttm)

4.10M

Revenue Per Share(ttm)

0.04

Gross Profit(ttm)

4.10M

EBITDA(ttm)3

-627.33M

Net Income Available to Common(ttm)

-568.53M

Diluted EPS(ttm)

-6.52

Share Statistics

Beta (5Y Monthly)

1.80

52-Week Change

19.50%

S&P 500 52-Week Change

21.01%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

96.45M

Dividend Yield

0.00%

Float4

91.86M

% Held by Insiders

4.30%

% Held by Institutions

69.20%

Balance Sheet

Total Cash(mrq)

2.44B

Total Cash Per Share(mrq)

25.32

Total Debt(mrq)

585.47M

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.32%

Quick Ratio(mrq)

13.32%

Book Value Per Share(mrq)

20.04

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.84

Free Cash Flow(ytd)

-345.93M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement